HER2 IHC Antibody

<strong>HER2 IHC Antibody</strong>_x000D_ <strong>Catalog number:</strong> B2014788_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 mL_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> 2-8°C_x000D_ <strong>Keywords:</strong> HER2 IHC Antibody_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Wesoła M, Jeleń M. A Comparison of IHC and FISH Cytogenetic Methods in the Evaluation of HER2 Status in Breast Cancer Adv Clin Exp Med. 2015 Sep-Oct;24(5):899-903._x000D_ 2: Tarantino P, Gandini S, Nicolò E, Trillo P, Giugliano F, Zagami P, Vivanet G, Bellerba F, Trapani D, Marra A, Esposito A, Criscitiello C, Viale G, Curigliano G. Evolution of low HER2 expression between early and advanced-stage breast cancer Eur J Cancer. 2022 Mar;163:35-43._x000D_ 3: Hamilton E, Shastry M, Shiller SM, Ren R. Targeting HER2 heterogeneity in breast cancer Cancer Treat Rev. 2021 Nov;100:102286._x000D_ 4: Rakha EA, Tan PH, Quinn C, Provenzano E, Shaaban AM, Deb R, Callagy G, Starczynski J, Lee AHS, Ellis IO 1, Pinder SE. UK recommendations for HER2 assessment in breast cancer: an update J Clin Pathol. 2023 Apr;76(4):217-227._x000D_ 5: Zhang H, Katerji H, Turner BM, Audeh W, Hicks DG. HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles Mod Pathol. 2022 Aug;35(8):1075-1082._x000D_ 6: Nicolò E, Boscolo Bielo L, Curigliano G, Tarantino P. The HER2-low revolution in breast oncology: steps forward and emerging challenges Ther Adv Med Oncol. 2023 Feb 9;15:17588359231152842._x000D_ 7: Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, Stoss O, Hill J, Ng V, Lehle M, Thomas M, Kiermaier A, Rüschoff J. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer Gastric Cancer. 2015 Jul;18(3):476-84._x000D_ 8: Ahn S, Woo JW, Lee K, Park SY. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation J Pathol Transl Med. 2020 Jan;54(1):34-44._x000D_ 9: Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study Histopathology. 2008 Jun;52(7):797-805._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/35970977">10: Rüschoff J, Friedrich M, Nagelmeier I, Kirchner M, Andresen LM, Salomon K, Portier B, Sredni ST, Schildhaus HU, Jasani B, Grzelinski M, Viale G. Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status Virchows Arch. 2022 Nov;481(5):685-694. </a>_x000D_ _x000D_ <strong>Products Related to HER2 IHC Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>